Analysing p53 tumour suppressor functions in mice

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 1, 2003, Pages 89-99

  Sluss, Hayla K ^a   Jones, Stephen N ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Ataxia telangiectasia mutant (ATM); Cancer; Cell cycle control; Genome integrity; Li Fraumeni familial cancer; Mdm 2; p53; Signal transduction; Tumour suppression

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR;

CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL GROWTH; DNA DAMAGE; DNA REPAIR; FAMILIAL CANCER; GENE ACTIVITY; GENE FUNCTION; GENE INACTIVATION; GENE INDUCTION; GENE MUTATION; GENOME; MEDICAL RESEARCH; MITOSIS INHIBITION; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ACETYLATION; AGING; ALLELES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE TARGETING; GENES, P53; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; MUTATION; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037315094     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.1.89     Document Type: Review

References (82)

1. STEELE RJ, THOMPSON AM, HALL PA, LANE DP: The p53 tumour suppressor gene. Br. J. Surg. (1998) 85:1460-1467.
2. EVANS SC, LOZANO G: The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol. Med. Today (1997) 3:390-395.
3. GIACCIA AJ, KASTAN MB: The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. (1998) 12:2973-2983.
4. APPELLA E, ANDERSON CW: Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. (2001) 268:2764-2772.
5. ASHCROFT M, VOUSDEN KH: Regulation of p53 stability. Oncogene (1999) 18:7637-7643.
6. ASHCROFT M, TAYA Y, VOUSDEN KH: Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. (2000) 20:3224-3233.
7. ALARCON-VARGAS D, RONAI Z: p53-Mdm2 - the affair that never ends. Carcinogenesis (2002) 23:541-547.
8. OLINER JD, KINZLER KW, MELTZER PS, GEORGE DL, VOGELSTEIN B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature (1992) 358:80-83.
9. CHEN J, MARECHAL V, LEVINE AJ: Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. (1993) 13:4107-4114.
10. KUSSIE PH, GORINA S, MARECHAL V et al.: Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 274:948-953.
11. WADGAONKAR R, COLLINS T: Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. (1999) 274:13760-13767.
12. KOBET E, ZENG X, ZHU Y, KELLER D, LU H: MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA (2000) 97:12547-12552.
13. ITO A, LAI CH, ZHAO X et al.: p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. (2001) 20:1331-1340.
14. BARAK Y, JUVEN T, HAFFNER R, OREN M: mdm2 expression is induced by wild type p53 activity. EMBO J. (1993) 12:461-468.
15. JUVEN T, BARAK Y, ZAUBERMAN A, GEORGE DL, OREN M: Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene (1993) 8:3411-3416.
16. BARAK Y, GOTTLIEB E, JUVEN-GERSHON T, OREN M: Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev. (1994) 8:1739-1749.
17. ZAUBERMAN A, FLUSBERG D, HAUPT Y, BARAK Y, OREN M: A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. (1995) 23:2584-2592.
18. JONES SN, ROE AE, DONEHOWER LA, BRADLEY A: Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 378:206-208.
19. MONTES DE OCA LUNA R, WAGNER DS, LOZANO G: Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 378:203-206.
20. MICHAEL D, OREN M: The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. (2002) 12:53-59.
21. KAMIJO T, BODNER S, VAN DE KAMP E, RANDLE DH, SHERR CJ: Tumor spectrum in ARF-deficient mice. Cancer Res. (1999) 59:2217-2222.
22. D'ORAZI G, CECCHINELLI B, BRUNO T et al.: Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell. Biol. (2002) 4:11-19.
23. HAWLEY RS, FRIEND SH: Strange bedfellows in even stranger places: the role of ATM in meiotic cells, lymphocytes, tumors, and its functional links to p53. Genes Dev. (1996) 10:2383-2388.
24. XU Y, ASHLEY T, BRAINERD EE, BRONSON RT, MEYN MS, BALTIMORE D: Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. (1996) 10:2411-2422.
25. ELSON A, WANG Y, DAUGHERTY CJ et al.: Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. USA (1996) 93:13084-13089.
26. BARLOW C, HIROTSUNE S, PAYLOR R et al.: Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell (1996) 86:159-171.
27. TAVOR S, TAKEUCHI S, TSUKASAKI K et al.: Analysis of the CHK2 gene in lymphoid malignancies. Leuk. Lymphoma (2001) 42:517-520.
28. MILLER CW, IKEZOE T. KRUG U et al.: Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes Chromosomes Cancer (2002) 33:17-21.
29. MENOYO A, ALAZZOUZI H, ESPIN E, ARMENGOL M, YAMAMOTO H, SCHWARTZ S Jr: Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. (2001) 61:7727-7730.
30. BERTONI F, CODEGONI AM, FURLAN D, TIBILETTI MG, CAPELLA C, BROGGINI M.: CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers. Genes Chromosomes Cancer (1999) 26:176-180.
31. VAZIRI H, DESSAIN SK, NG EATON E et al.: hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 107:149-159.
32. BELL DW, VARLEY JM, SZYDLO TE et al.: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 286:2528-2531.
33. TAKAI H, TOMINAGA K, MOTOYAMA N et al.: Aberrant cell cycle checkpoint function and early embryonic death in Chk1 (-/-) mice. Genes Dev. (2000) 14:1439-1447.
34. LIU Q, GUNTUKU S, CUI XS et al.: Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev. (2000) 14:1448-1459.
35. HIRAO A, KONG YY, MATSUOKA S et al.: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science (2000) 287:1824-1827.
36. DONEHOWER LA, HARVEY M, SLAGLE BL et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 356:215-221.
37. JACKS T, REMINGTON L, WILLIAMS BO et al.: Tumor spectrum analysis in p53-mutant mice. Curr. Biol. (1994) 4:1-7.
38. ARMSTRONG JF, KAUFMAN MH, HARRISON DJ, CLARKE AR: High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. (1995) 5:931-936.
39. SAH VP, ATTARDI LD, MULLIGAN GJ, WILLIAMS BO, BRONSON RT, JACKS T: A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. (1995) 10:175-180.
40. HARVEY M, MCARTHUR MJ, MONTGOMERY CA JR., BRADLEY A, DONEHOWER LA: Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. (1993) 7:938-943.
41. KUPERWASSER C, HURLBUT GD, KITTRELL FS: Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol. (2000) 157:2151-2159.
42. SOUSSI T, BEROUD C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev Cancer (2001) 1:233-240.
43. VENKATACHALAM S, SHI YP, JONES SN et al.: Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. (1998) 17:4657-4667.
44. ARTANDI SE, CHANG S, LEE SL et al.: Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature (2000) 406:641-645.
45. BERG LJ: Molecular determinants of TCR expression and selection. Curr. Opin. Immunol. (2001) 13:232-241.
46. LIAO MJ, ZHANG XX, HILL R et al.: No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol. Cell. Biol. (1998) 18:3495-3501.
47. NACHT M, JACKS T: V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. Cell Growth Differ. (1998) 9:131-138.
48. GUIDOS CJ, WILLIAMS CJ, GRANDAL I, KNOWLES G, HUANG MT, DANSKA JS: V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors. Genes Dev. (1996) 10:2038-2054.
49. NACHT M, STRASSER A, CHAN YR et al.: Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev. (1996) 10:2055-2066.
50. HARVEY M, SANDS AT, WEISS RS et al.: In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 8:2457-2467.
51. BOREL F, LOHEZ OD, LACROIX FB, MARGOLIS RL: Mutiple centrosomes arise from tetraploidy checkpoint failure and mitotic centrosome clusters in p53 and RB pocket protein-compromised cells. PNAS (2002) 99:9819-9824.
52. LIVINGSTONE LR, WHITE A, SPROUSE J, LIVANOS E, JACKS T, TLSTY TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell (1992) 70:923-935.
53. HOLLANDER MC, SHEIKH MS, BULAVIN DV et al.: Genomic instability in Gadd45a-deficient mice. Nat. Genet. (1999) 23:176-184.
54. SHAO C, DENG L, HENEGARIU O, LIANG L, STAMBROOK PJ, TISCHFIELD JA: Chromosome instability contributes to loss of heterozygosity in mice lacking p53. Proc. Natl. Acad. Sci. USA (2000) 97:7405-7410.
55. BUNZ F, FAUTH C, SPEICHER MR et al.: Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res. (2002) 62:1129-1133.
56. CAHILL DP, LENGAUER C, YU J et al.: Mutations of mitotic checkpoint genes in human cancers. Nature (1998) 392:300-303.
57. YONISH-ROUACH E, RESNITZKY D, LOTEM J, SACHS L, KIMCHI A, OREN M: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (1991) 352:345-347.
58. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTEIN B, CRAIG RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res. (1991) 51:6304-6311.
59. KASTAN MB, ZHAN Q, EL-DEIRY WS et al.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell (1992) 71:587-597.
60. EL-DEIRY WS, TOKINO T, VELCULESCU VE et al.: WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 75:817-825.
61. BRUGAROLAS J, MOBERG K, BOYD SD, TAYA Y, JACKS T, LEES JA: Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc. Natl. Acad. Sci. USA (1999) 96:1002-1007,
62. BRUGAROLAS J, CHANDRASEKARAN C, GORDON J, BEACH D, JACKS T, HANNON G: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (1995) 377:552-557.
63. DENG C, ZHANG P, HARPER W, ELLEDGE S, LEDER P: Mice lacking p21 CIP/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell (1995) 82:675-684.
64. LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA, JACKS T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (1993) 362:847-849.
65. CLARKE AR, PURDIE CA, HARRISON DJ et al.: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (1993) 362:849-852.
66. LOWE SW, RULEY HE, JACKS T, HOUSMAN DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell (1993) 74:957-967.
67. XU X, WAGNER KU, LARSON D et al.: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. (1999) 22:37-43.
68. XU X, QIAO W, LINKE SP et al.: Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. (2001) 28:266-271.
69. MARINO S, VOOIJS M, VAN DER GULDEN H, JONKERS J, BERNS A: Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. (2000) 14:994-1004.
70. SUZUKI A, DE LA POMPA JL, HAKEM R et al.: Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev. (1997) 11:1242-1252.
71. JONKERS J, MEUWISSEN R, VAN DER GULDEN H, PETERSE H, VAN DER VALK M, BERNS A: Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. (2001) 4:418-425.
72. ROEMER K, MUELLER-LANTZSCH N: p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis. Oncogene (1996) 12:2069-2079.
73. CHAO C, SAITO S, KANG J, ANDERSON CW, APPELLA E, XU Y: p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. (2000) 19:4967-4975.
74. JIMENEZ GS, NISTER M, STOMMEL JM et al.: A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. (2000) 26:37-43.
75. KO LJ, PRIVES C: p53: puzzle and paradigm. Genes Dev. (1996) 10:1054-1072.
76. LIU G, MCDONNELL TJ, MONTES DE OCA LUNA R et al.: High metastatic potential in mice inheriting a targeted p53 mis-sense mutation. Proc. Natl. Acad. Sci. USA (2000) 97:4174-4179.
77. DE VRIES A, FLORES ER, MIRANDA B et al.: Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA (2002) 99:2948-2953.
78. CHAO C, SAITO S, ANDERSON CW, APPELLA E, XU Y: Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA (2000) 97:11936-11941.
79. SCHMIDT-KASTNER PK, JARDINE K, CORMIER M, MCBURNEY MW: Absence of p53-dcpendent cell cycle regulation in pluripotent mouse cell lines. Oncogene (1998) 16:3003-3011.
80. TYNER SD, VENKATACHALAM S, CHOI J et al.: p53 mutant mice that display early ageing-associated phenotypes. Nature (2002) 415:45-53.
81. LOMBARD DB, BEARD C, JOHNSON B et al.: Mutations in the WRN gene in mice accelerate mortality in a p53-null background. Mol. Cell Biol. (2000) 20:3286-3291.
82. WU Z, EARLE J, SAITO S et al.: Mutation of mouse p53 Ser23 and the response to DNA damage. Mol. Cell Biol. (2002) 22:2441-2449.